BACKGROUND: Gap junction remodeling is well established as a consistent feature of human heart disease involving spontaneous ventricular arrhythmia. The mechanisms responsible for gap junction remodeling that include alterations in the distribution of, and protein expression within, gap junctions are still debated. Studies reveal that multiple transcriptional and posttranscriptional regulatory pathways are triggered in response to cardiac disease, such as those involving RNA-binding proteins. The expression levels of FXR1 (fragile X mental retardation autosomal homolog 1), an RNA-binding protein, are critical to maintain proper cardiac muscle function; however, the connection between FXR1 and disease is not clear.
V entricular arrhythmias in patients with dilated cardiomyopathy (DCM) result in an increased risk for sudden cardiac death. 1 In DCM, alterations in cell-cell connections at intercalated discs compromise the structural integrity of the heart (for review 2 ). Connections at the intercalated disc consist of 3 complexes: fascia adherens and desmosomes that anchor cardiomyocytes together, and gap junctions that allow for cell-cell communication. Contributing to arrhythmogenesis are alterations in the distribution of, and protein expression within, gap junctions that allow chemical and electric coupling between cardiomyocytes, a process known as gap junction remodeling (for review 3 ). Downregulation of Cx43 (connexin 43), the predominant connexin expressed in ventricles, is a typical feature of gap junction remodeling linked to the development of arrhythmias in human cardiomyopathies. [4] [5] [6] Several proteins have been implicated in the gap junction remodeling process such as ZO-1 (zonula occludens-1) (for review 7 ) . ZO-1 localizes to the intercalated disc where it regulates the organization of gap junctions and adherens junctions (eg, 8 ). ZO-1 directly interacts with Cx43 and affects Cx43 expression and gap junction plaque size. [9] [10] [11] It is interesting to note that upregulation of ZO-1 protein levels is also seen in human dilated and ischemic cardiomyopathies. 11 The mechanism regulating Cx43 and ZO-1 expression during cardiac disease progression is still undefined.
Dysregulation of RNA-binding proteins is implicated in many diseases including cardiomyopathies, cancers, neurological disorders, and muscular atrophies (for review 12 ). Important in cardiac development and disease is the RNA-binding protein, FXR1 (fragile X mental retardation syndrome-related protein 1). [13] [14] [15] FXR1 is a member of the fragile X family of RNA-binding proteins (FraX), which includes FMRP, FXR1, and FXR2. FraX members can form hetero-and homodimers, and larger complexes with additional proteins. 16 Each member contains 3 RNA-binding domains (2 KH domains; 1 RGG box). The RNA-recognition element for the KH domain can bind kissing complex RNA motifs, whereas the RGG box recognizes G quadruplexes. 17, 18 Both of these RNA-binding domains allow FraX members to control expression of an assortment of mRNA targets.
Previous studies primarily focused on FMRP, because the absence of, or mutations in, FMRP leads to fragile X syndrome; this is the most common form of inherited mental retardation and autism in humans. FXR1 is the only isoform with robust expression in striated muscle, where it localizes to puncta in the cytosol and is enriched at Z discs (border of sarcomeres). 13, 19 Ablation of Fxr1 in mice results in perinatal lethality most likely attributable to cardiac defects, whereas a reduction of FXR1 protein expression in zebrafish results in cardiomyopathy. [13] [14] [15] FXR1 has been shown to directly regulate various transcripts (ie, desmoplakin, talin2, tumor necrosis factor-α, and p21), in addition to interacting with the microRNA pathway (via Dicer and Argonaute2 binding), supporting its role as an important regulator in the heart. 15, [20] [21] [22] [23] Despite the essential importance of FXR1 in cardiac function, surprisingly few direct targets have been identified.
To test our hypothesis that FXR1 is an important regulator of gap junction downregulation in human cardiomyopathy, FXR1 expression in human left ventricle DCM biopsy samples was examined and assessed for its role in regulating levels of prominent gap junction components. FXR1 expression is significantly increased in human DCM samples, and in mouse models of DCM. FXR1 associates with intercalated discs; directly interacts with Cx43, Cx45, and ZO-1 mRNA; and can regulate Cx43, Cx45, and ZO-1 protein levels via translational regulation and mRNA stability. Furthermore, upregulation of FXR1 in the heart promotes redistribution of gap junctions and subsequently regulates ventricular tachycardia in mice. Although loss of FXR1 in the heart leads to DCM, no change in Cx43 expression is observed, as is observed in hearts from other DCM models. Taken together, we demonstrate that FXR1 directly regulates critical gap junction proteins and maintains cardiac conduction. We provide a potential mechanism of ventricular arrhythmias, whereby gap junction remodeling is directly regulated by FXR1.
Clinical Perspective
What Is New?
• FXR1 (fragile X mental retardation autosomal homolog 1) expression is significantly increased in human and mouse dilated cardiomyopathy (DCM).
• Upregulation of FXR1 in the heart alters localization and distribution of gap junctions subsequently leading to ventricular tachycardia in mice.
• FXR1 associates with intercalated discs and directly interacts with Cx43 (connexin 43), Cx45 (connexin 45), and ZO-1 (zonula occludens-1) mRNA to regulate their expression in cardiomyocytes.
• Loss of FXR1 in the heart leads to DCM with no observable change in Cx43 expression, as is seen in hearts from other DCM models.
What Are the Clinical Implications?
• The present study identifies a novel mechanism whereby the RNA-binding protein FXR1 directly regulates gap junction remodeling, leading to DCM.
• FXR1 is a promising target for therapeutic strategies to improve gap junction function in DCM.
METHODS
An expanded Methods is available in the online-only Data Supplement. The data and methods will be made available to other researchers for purposes of reproducing the results or replicating the procedure via email contact with the corresponding author.
Tissue from Nonfailing and Failing Human Hearts
Well-characterized samples of left ventricle (LV) tissue from patients with nonfailing or failing (nonischemic DCM) hearts were obtained from the Loyola University Health System Cardiovascular Institute Tissue Repository and Gift of Hope Organ and Tissue Donor Network as published. [24] [25] [26] [27] Following institutional review committee approval from the Loyola University Health System and the University of Arizona, and informed consent from organ donor family members or patients undergoing heart transplantation, tissue samples were surgically removed, frozen in liquid N 2 , and stored at −80°C.
Mouse Models
LMOD2 (Leiomodin 2) knockout mice are in C57BL/6J background 28 ; samples used for immunoblotting were collected from 19-day-old mice. MLP (muscle LIM protein) knockout mice are in a mixed SV129/Black Swiss background 29 ; samples used for immunoblotting were collected from 2-monthold male mice. Conditional FXR1 knockout mice (fxr1 f/f ) were obtained from Baylor College of Medicine and crossed onto Myh6-Cre knock-in line for cardiac-specific knockout. Mice were maintained in accordance with institutional guidelines and procedures approved by the Institutional Animal Care and Use Committee at the University of Arizona.
Statistics
A Student t test was used to determine significance for protein and mRNA levels in human and mouse samples, and for gap junction plaque size and Cx43 localization. For luciferase assay, a Student t test was used to compare each individual luciferase construct between treatment groups. To determine statistical significance, a 1-way ANOVA with post hoc Tukey was used for protein and mRNA levels in cardiomyocytes, a 2-way ANOVA with post hoc Bonferroni was used for the polysome assay, a 2-way repeated-measures ANOVA with post hoc Bonferroni was used for the RNA stability assay, and an unpaired t test was used to analyze the statistical difference in the presence or absence of ventricular tachycardia between groups.
RESULTS

FXR1 Protein Is Upregulated in Human and Mouse Models of DCM
To assess the role of FXR1 in human cardiac disease, we quantitatively analyzed FXR1 protein expression levels in biopsies from patients with DCM. We found that FXR1 protein is significantly increased (1.61±0.231, P<0.05) in LVs from patients with DCM, with no change in FXR1 mRNA detected (data shown for protein in Figure 1A and 1B). These results suggest that FXR1 protein expression levels are linked to human DCM disease. To determine whether FXR1 upregulation contributes to the development of DCM and whether FXR1 is a common feature of cardiomyopathies, we studied MLP knockout mice that are among the most extensively characterized mouse model for DCM and display ventricular chamber enlargement at 2 months (eg, 29 ). FXR1 levels were also investigated in LMOD2 knockout mice, which we reported display a rapid ventricular chamber enlargement consistent with DCM clearly evident at day 15, but they die shortly after as juveniles. 28 Quantification of FXR1 protein levels in LV tissue samples from MLP ( Figure 1C and 1D ) and LMOD2 knockout (KO) ( Figure 1E and 1F 
FXR1 Localizes With Intercalated Discs
To determine if FXR1 functions at the intercalated disc, a BioID proximity assay was performed to identify whether FXR1 interacts with any proteins in this cellular location. A MycBirA*-FXR1 fusion protein was expressed in neonatal cardiomyocytes. The expression of full-length fusion protein ( Figure 2A ) and overall enrichment of biotinylated proteins ( Figure 2B ) were confirmed. To identify novel protein interactors, a BioID pull-down was performed and candidate proteins were identified by Western blot analysis. ZO-1 and N-cadherin were identified as potential interactors of FXR1 ( Figure 2C ), suggesting that FXR1 may be functionally associated with intercalated discs.
Previous studies reported that FXR1 localizes to puncta in the cytosol (eg, associated with stress granules 30 ) and is enriched at Z discs (border of sarcomeres). 13, 19 To determine if FXR1 also localizes to intercalated discs, immunofluorescence imaging on adult mice LV tissue sections was performed. FXR1 localized to cytosolic puncta and enriched at most intercalated discs when costained for plakoglobin, a marker of intercalated discs ( Figure 2D ). This localization at intercalated discs is consistent with our previous report that FXR1 regulates the expression of the desmosomal protein desmoplakin in cardiomyocytes.
15
FXR1 Directly Interacts With Cx43, Cx45, and ZO-1 mRNAs
Altered structural integrity in DCM commonly leads to changes in composition and structure of the intercalated disc, in particular, gap junction remodeling, leading to increased arrhythmogenic risk (eg, 31 ). To investigate if FXR1 regulates the integrity of gap junctions, we determined whether mRNAs encoding any major gap junction proteins of the LV are targets of FXR1. Fragile X family members interact with nucleotide sequences capable of forming G quadruplexes. QGRS Mapper was used for predicting G quadruplexes in nucleotide sequences in 13, 19 ), it is also specifically enriched in close proximity to intercalated discs as marked by anti-plakoglobin antibodies (green). Yellow arrowhead marks FXR1 at the intercalated disc; magenta arrowhead marks intercalated disc without detectable FXR1. Scale bar=10 μm. Cx43 indicates connexin 43; FXR1, fragile X mental retardation autosomal homolog 1; HRP, horseradish peroxidase; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; and ZO-1, zonula occludens-1.
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the primary gap junction proteins: Cx43, Cx45, and ZO-1 mRNA sequences. 32 We also examined G quadruplexes in additional intercalated disc proteins: desmoplakin, a FXR1 mRNA target, 15 and N-cadherin, identified as a potential protein interactor of FXR1 in the BioID pull-down assay ( Figure 2C ) and as a protein involved in formation and function of gap junctions (eg, 33 ). The results show that a majority of G quadruplexes are located within the coding region of Cx43, Cx45, ZO-1, N-cadherin, and desmoplakin mRNA ( Table I in the online-only Data Supplement), suggesting that these mRNAs may interact with (and be regulated by) FXR1.
To determine if Cx43, Cx45, or ZO-1 mRNA are indeed present in the FXR1 RNA-immunoprecipitation complex, an RNA immunoprecipitation was performed to isolate FXR1 protein-RNA complexes from nonfailing human LV tissue ( Figure 3A ). End point polymerase chain reaction was used to detect transcripts whose cognate proteins are major constituents of gap junctions in the LV (see Table II in the online-only Data Supplement for primers). Cx43, Cx45, and ZO-1 mRNA transcripts are reproducibly identified in FXR1 RNA immunoprecipitations (Figure 3D ). Little to no signal is detected in immunoglobulin immunoprecipitation control, indicating that amplification is specific for RNA associated with FXR1. Next, FXR1 protein-RNA complexes were isolated from adult mouse heart tissue ( Figure 3B ) and cultured rat cardiomyocytes ( Figure 3C ); Cx43, Cx45, and ZO-1 mRNA are present in the FXR1 protein-RNA complex ( Figure 3E and 3F). To determine if these interactions with FXR1 are direct, a direct binding assay was performed. Based on predicted G-quadruplex results, coding sequences of Cx43, Cx45, and ZO-1 mRNAs were synthesized by in vitro transcription, labeled with biotin, and incubated with recombinant FXR1. At 50 to 150 pmol of transcript, FXR1 protein binds directly to Cx43, Cx45, and ZO-1, but not β2 microglobulin mRNA (negative control) ( Figure 3G ). Thus, FXR1 can bind directly to Cx43, Cx45, and ZO-1 mRNA, allowing for possible posttranscriptional regulation of gap junction remodeling.
FXR1 Regulates Cx43 and ZO-1 Protein Expression
FXR1 plays a critical role in translational regulation by interacting with target mRNAs. Because FXR1 interacts with mRNAs encoding major gap junction proteins, it was determined whether FXR1 regulates their protein expression. Primary rat cardiomyocytes were transduced with different multiplicity of infections (MOIs) of FXR1 or β-galactosidase adenovirus. Western blot analysis confirmed increased expression of FXR1 protein ranging from 5-to 10-fold in cells transduced with FXR1 adenovirus ( Figure 4A and 4B). Cx43 is significantly repressed in a dose-dependent manner in response to increased FXR1 expression levels ( Figure 4A and 4C). Next, it was determined whether alterations in protein levels of Cx43 are attributable to effects on transcript levels. Reverse transcription polymerase chain reaction showed that Cx43 mRNA is significantly reduced in cells with increased Several studies show that ZO-1 plays a critical role in gap junction organization by interacting with Cx43 , D) , mouse left ventricle (B, E), or rat cardiomyocytes (C, F) by using anti-FXR1 antibodies or IgG as a control. A, B, and C, Proteins from precipitated fractions were resolved on a SDS-polyacrylamide gel and subjected to immunoblotting (IB) with anti-FXR1 antibodies. FXR1 was detected in the FXR1-bound fraction but not in the IgG-bound fraction. D, E, and F, RNA isolated from the FXR1 RNA-IP was subjected to RT-PCR analysis using Cx43, Cx45, and ZO-1 primers. All 3 targets were detected in the FXR1-bound fraction but not in the IgG-bound fraction. G, Biotin-labeled β2 microglobulin (negative control), Cx43, Cx45, and ZO-1 mRNAs were incubated with recombinant FXR1 protein. The complex was resolved on a SDS-polyacrylamide gel and subjected to immunoblotting with anti-FXR1 antibodies. FXR1 bound to Cx43, Cx45, and ZO-1 mRNA, but not β2 microglobulin mRNA. Cx43 indicates connexin 43; Cx45, connexin 45; FXR1, fragile X mental retardation autosomal homolog 1; IgG, immunoglobulin G; RT-PCR, reverse transcription polymerase chain reaction; SDS, sodium dodecyl sulfate; and ZO-1, zonula occludens-1.
protein. Because FXR1 interacts with ZO-1 protein and mRNA ( Figures 2C and 3) , whether ZO-1 protein levels are also regulated by FXR1 was investigated. It is interesting to note that, in neonatal rat cardiomyocytes transduced with different MOIs of FXR1, ZO-1 levels are significantly increased at low levels (10 MOI) and reduced at high levels of FXR1 expression (20 MOI) (Figure 4A and 4D) . Alterations in protein levels of ZO-1 are attributable to effects at the transcript level. Reverse transcription polymerase chain reaction showed that ZO-1 mRNA levels are not changed ( Figure IB in the online-only Data Supplement), suggesting thatFXR1 regulates ZO-1 through a translational mechanism.
Upregulation of Cx45 has been reported in patients who have heart failure (ie, those with dilated or ischemic cardiomyopathy), possibly compensating for reduced Cx43 levels. 34 Therefore, Cx45 protein and mRNA levels in neonatal rat cardiomyocytes overexpressing FXR1 were analyzed. It is interesting to note that, whereas Cx45 protein levels are unchanged ( 
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FXR1 levels in DCM can contribute to the regulation of major gap junction proteins by multiple transcriptional and translation mechanisms depending on the specific target it is regulating.
FXR1 Is Involved in Translational Regulation and mRNA Stability
To examine whether FXR1 controls Cx43, Cx45, and ZO-1 through translational regulation, polysome fractionation was performed from cardiomyocytes transduced with 10 MOI of FXR1 or β-galactosidase adenovirus. Western blot analysis shows that FXR1 associates with both untranslated fractions (ribonucleoproteins and ribosomal subunits) and actively translating polyribosomes ( Figure 5A ). Overexpression of FXR1 causes a slight increase in FXR1 protein associated with the heavy polysome fraction (ie, actively translating fraction) in comparison with HuR, which does not change its distribution ( Figure 5B ). These results are consistent with FXR1 being involved in translational regulation. Consequently, if FXR1 regulates its mRNA target translation, polysome fractionation could show either a shift in the target mRNA associated with heavy polysome fraction or a change in total target mRNA in the polysome fraction. To determine the distribution of Cx43, Cx45, and ZO-1, each fraction from the gradient was analyzed by reverse transcription polymerase chain reaction. Cx43 mRNA distribution is not changed on FXR1 overexpression (Figure VIB in the online-only Data Supplement), but there is a decrease in total Cx43 mRNA in the polysome fraction (Figure 5C ). On the contrary, there is a reduction in ZO-1 mRNA in the actively translating polysome fraction on FXR1 overexpression (Figure VIC in the online-only Data Supplement), but no change in total ZO-1 mRNA levels in the polysome fraction ( Figure 5C ). No change was observed in Cx45 mRNA distribution and its total levels in the polysome fraction ( Figure 5C ; Figure VID in the online-only Data Supplement). Neonatal cardiomyocytes were transduced with Adv-FXR1 (10 MOI) or Adv β-galactosidase (β-gal, 10 MOI) for 72 hours, and ribosomes from equivalent amounts of total RNA were fractionated (n=3). A, FXR1 protein expression in different fractions from polysome profile reveals that FXR1 associates with both the RNP and polysome fractions. B, Distribution of FXR1 and HuR protein levels (reported as percent FXR1 or HuR protein in each fraction divided by total FXR1 or HuR protein) in the polysome profile. A slight increase in FXR1 protein associated with the heavy polysome fraction is seen, whereas no change is seen in HuR protein. C, Percent of total Cx43 mRNA level (70.29% of control) is reduced in the polysome fraction in FXR1 overexpression cells, but no change is seen for 18S, Cx45, and ZO-1 mRNA. Student t test was used to calculate statistical significance (n=3). D, Luciferase activity is significantly reduced for pMirCx43 in cells expressing FXR1 (65.21% of shLuc in comparison with shFXR1). No change was seen for pMirZO-1 or pMirCx45 or the negative control pMirβ2 microglobulin in cells (Continued ) Figure 5 Continued. expressing FXR1 (shLuc) in comparison with control (shFXR). pMir vector alone serves as control that is not translationally repressed by FXR1. Student t test analysis was used to calculate statistical significance for each pMir construct: *P<0.05. E, Graph of Cx43 plaque sizes expressed as the percentage of β-gal control (average 22.29±0.605% smaller in FXR1 versus β-gal). Data are means±SEM (n=3, average of 10 cells from 3 independent cultures). Student t test was used to calculate statistical significance: **P<0.01. F, Representative set of deconvolution images showing a decrease in Cx43 plaque size in cells overexpressing FXR1. Scale bar=10 μm. Cx43 indicates connexin 43; Cx45, connexin 45; FXR1, fragile X mental retardation autosomal homolog 1; β-gal, β-galactosidase; MOI, multiplicity of infection; Pon S, Ponceau S; RNP, ribonucleoprotein; and ZO-1, zonula occludens-1.
To further confirm whether FXR1 regulates translation of Cx43, Cx45, and ZO-1, we used an in vitro dual luciferase assay. In this assay, coding sequences of Cx43, Cx45, and ZO-1 mRNA were inserted downstream of a pMirGLO dual-luciferase vector (pMir) and cotransfected with shFXR1 to knockdown FXR1 expression or shLuc (control) into C2C12 cells. Transfection efficiency and cell viability were monitored by using Renilla luciferase, and data reported as Firefly:Renilla ratios normalized to pMir for each sample. Luciferase activity is significantly reduced for Cx43 in cells expressing FXR1 (65.2% of shLuc in comparison with shFXR1, P<0.05; Figure 5D ). No change was seen for ZO-1 and Cx45 in cells expressing FXR1 ( Figure 5D ). These results demonstrate that FXR1 regulates translation of Cx43, but may regulate ZO-1 and Cx45 through other mechanisms.
Although no change was seen in Cx45 protein expression, an increase in Cx45 mRNA was seen on FXR1 overexpression ( Figure I in the online-only Data Supplement). To determine whether Cx45 is regulated transcriptionally via stabilization of its RNA, we performed RNA stability assays on rat cardiomyocytes treated with actinomycin D to block transcription. RNA was isolated after 0, 3, 6, or 12 hours, and the levels of Cx43, Cx45, and ZO-1 mRNAs were measured by reverse transcription polymerase chain reaction. Cx45 and ZO-1 mRNAs are significantly more stable in cardiomyocytes overexpressing FXR1 (T 1/2 Cx45=4.5 hours, ZO-1=9.3 hours), in comparison with control cardiomyocytes overexpressing β-galactosidase (T 1/2 Cx45=2.7 hours, ZO-1=3.3 hours) (Figure VII in the online-only Data Supplement). Conversely, Cx43 mRNA stability is not changed between the 2 groups. Together, these results indicate that FXR1 can regulate Cx45 and ZO-1 but not Cx43 mRNA stability.
Gap Junction Plaque Size Is Reduced When FXR1 Levels Are Elevated
In DCM, gap junction remodeling includes a decrease in Cx43 expression and a reduction in gap junction plaque size. 11 Increased expression of FXR1 in neonatal rat cardiomyocytes leads to a significant reduction in Cx43 protein ( Figure 4C ). To examine gap junction plaque size, immunofluorescence imaging was performed. Cardiomyocytes were plated on patterned plates to enhance cell-to-cell contact and gap junction formation. Immunofluorescence staining of Cx43 shows visibly smaller gap junction plaques ( Figure 5F ). Quantification of plaques confirmed that gap junction plaques are on average smaller in cells expressing increased levels of FXR1 (22.29±0.605%, P<0.001) versus β-galactosidase control ( Figure 5E ). This result supports our hypothesis that FXR1 translationally represses Cx43 protein leading to a reduction in gap junction plaque size.
FXR1 Overexpression in Mice Promotes Gap Junction Redistribution Plus Ventricular Tachycardia
To better understand the role of FXR1 in gap junction remodeling in vivo, we increased the levels of FXR1 in hearts of C57BL/6 mice via injection of 3xMyc-FXR1 adeno-associated virus (AAV). With a significant increase in FXR1 protein (7.33±1.62, P<0.01), Cx43 protein expression is significantly reduced (0.81±0.028, P<0.05) with no change in Cx43 mRNA; this result is consistent with that observed with elevated FXR1 levels in neonatal cardiomyocytes (data shown for protein in Figure 6A through 6C). No change was observed for Figure 6 . Overexpression of FXR1 in mouse heart reduces Cx43 protein expression. AAV-3xMyc-FXR1 was injected into D4 C57BL/6 mice and at D56 collected. A, Representative immunoblots of control and AAV-3xMyc-FXR1-injected mice. Left ventricle lysates probed for FXR1, Myc, Cx43, Cx45, and ZO-1 plus Ponceau S staining (for actin) of the blot used for normalization. B, FXR1 protein expression levels in AAV-3xMyc-FXR1-injected mice were significantly increased (n=5; 7.33±1.62, P=0.01) in comparison with control (n=4). C, In AAV-3xMyc-FXR1-injected mice, Cx43 protein expression is significantly reduced (0.809±0.028, P<0.05) in comparison with control. Cx45 (D) and ZO-1 (E) protein levels are both unchanged. Student t test was used to calculate statistical significance: *P<0.05. **P<0.01. AAV indicates adeno-associated virus; Cx43, connexin 43; Cx45, connexin 45; FXR1, fragile X mental retardation autosomal homolog 1; Pon S, Ponceau S; and ZO-1, zonula occludens-1.
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both ZO-1 and Cx45 protein and mRNA levels (data shown for protein in Figure 6A , 6D, and 6E). Immunofluorescence analysis confirmed a 29.7% reduction in Cx43 at the intercalated disc (as marked by the presence of plakoglobin) in LV sections from 3xMyc-FXR1 AAV-injected mice ( Figure 7C and 7D) . More than 50% of cells that were enriched for FXR1 show variable levels of redistribution of Cx43 to lateral interfaces between cardiomyocytes ( Figure 7D ). This significant change in distribution of Cx43 is predicted to enhance reentry circuits in the myocardium that enable ventricular tachycardia.
Echocardiography and electrophysiological studies were performed on the transduced mice. Echocardiography shows no functional difference between 3xMyc-FXR1 AAV-injected and control mice ( Figure VIII in the online-only Data Supplement). On programmed electric stimulation, FXR1-transduced mice had inducible ventricular tachycardia (100%), whereas control mice did not (0%) (P<0.05) ( Figure 7A and 7B). These data suggest that FXR1 expression level is critical to maintain proper gap junction protein expression and assembly in cardiomyocytes. Misregulation of FXR1 in vivo can augment the gap junction remodeling in cardiac disease and contribute to myocardial electric abnormalities.
Cardiac-Specific Loss of FXR1 Leads to DCM
To determine whether FXR1 regulates gap junction remodeling in DCM, a conditional loss-of-function approach was taken, using a floxed fxr1 allele (fxr1 f/f ). To generate cardiac-specific FXR1 knockout (cKO) mice, Cre recombinase was expressed from cardiacspecific alpha-myosin heavy chain promoter. 36 Immunoblot analysis revealed no detectable FXR1 protein expression in LV of cKO mice ( Figure 8C ). The cKO mice appear indistinguishable from their wild-type littermates and have no overt signs of distress at 2 AAV-3xMyc-FXR1 was injected into day 4 C57BL/6 mice. Electrophysiology studies were performed between 2 and 3 months of age. A, Examples of normal or ventricular tachycardia in control mice and in AAV-3xMyc-FXR1-injected mice. In AAV-3xMyc-FXR1-injected mice, a monomorphic sustained ventricular tachycardia ensues for ≈4.3 seconds at a rate of ≈960 beats/min. Spontaneous recapture of the heart by the intrinsic conduction system terminates the sustained ventricular tachycardia, which is not seen in the control mice. B, AAV-3xMyc-FXR1-injected mice have a significant (n=4, P<0.05) incidence of sustained ventricular tachycardia, defined as >15 consecutive premature ventricular contractions, in comparison with control (n=5). An unpaired t test was used to calculate statistical significance. C, The percent of Cx43 fluorescence intensity at the intercalated disc (ICD; as marked by plakoglobin). There is a significant reduction in Cx43 at the ICD in AAV-3xMyc-FXR1-injected mice in comparison with control mice (n=20, 70.32±5.91%, P<0.001) versus cells with control levels of FXR1 (n=20, 100±3.98%). Student t test was used to calculate statistical significance: ***P<0.001. D, Representative confocal images showing overexpression of FXR1 (red) in AAV-3xMyc-FXR1-injected mice results in redistribution of Cx43 (blue) from the intercalated disc (marked by yellow arrowheads) to along the lateral membrane (marked by magenta arrows). Plakoglobin (green) marks the intercalated disc. Scale bar=10 μm. AAV indicates adeno-associated virus; Cx43, connexin 43; FXR1, fragile X mental retardation autosomal homolog 1; PVC, premature ventricular contraction; VT, ventricular tachycardia; and ZO-1, zonula occludens-1.
months. However, histological analysis of cKO hearts revealed enlarged ventricular lumens ( Figure 8A ). Transthoracic M-mode echocardiography at the level of the papillary muscle confirmed that cKO hearts display a DCM phenotype with a significant increase in LV internal diameter and eccentric index ( Figure 8B ). It is surprising that Cx43 and Cx45 protein and mRNA expression are not altered ( Figure 8C , Figure IX in the online-only Data Supplement), whereas ZO-1 protein is significantly increased ( Figure 8C ). The increase in ZO-1 protein is consistent with the change seen in our other DCM mouse models (ie, MLP-and LMOD2-KO, Figures IV and V in the online-only Data Supplement) and seems to be a common feature of DCM. Although ZO-1 protein is increased, its mRNA is significantly decreased in cKO mice and supports the role that FXR1 stabilizes ZO-1 mRNA ( Figure VII in the online-only Data Supplement). The fact that FXR1 cKO hearts are dilated, but there is no change in Cx43 protein expression as is commonly seen in other DCM samples (eg, human and mouse models of DCM), is (1) consistent with our observation that upregulation of FXR1 in DCM reduces Cx43 expression, and (2) strongly supports our hypothesis that FXR1 directly regulates Cx43 expression. Together, using cardiac-specific FXR1 KO mice, we have demonstrated that FXR1 protein expression is involved in gap junction remodeling seen in DCM.
DISCUSSION
Dysregulation of the intercalated disc may contribute importantly to the phenotype of DCM and arrhythmia that is a major cause of morbidity and mortality. Understanding the precise mechanism by which gap junctions become abnormal may lead to new therapeutic targets for patients with heart failure attributable to DCM. Studies investigating the expression and localization of intercalated disc proteins in mouse models of DCM show that several proteins are significantly altered, including ZO-1 and Cx43 (for review 37 ). Changes in these proteins reduce cell-cell coupling and contribute to a more arrhythmogenic phenotype; the regulatory mechanism controlling the expression of these proteins is unknown. Because no direct links between gap junctional complex proteins and mRNA expression were reported before this investigation, the possibility was left open that posttranscriptional regulation is an important mechanism in the progression of cardiac disease. In fact, several studies have 
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demonstrated that RNA-binding proteins play a role in cardiac development and disease, but how they do so is unknown (for review 38 ) . In this investigation, we discovered that the RNAbinding protein FXR1 is an important mediator of gap junction remodeling associated with DCM. FXR1 plays multiple, functional roles by differentially regulating each of its targets by a unique mechanism; this regulation appears to depend on FXR1 expression levels. In the LVs of human patients and mice with DCM, FXR1 protein expression is increased. This finding is consistent with data from gene-profiling studies of human patients with DCM, revealing that FXR1 is significantly upregulated.
39 FXR1 localizes to the intercalated disc and directly interacts with the coding sequence of the major gap junction components: Cx43, ZO-1, and Cx45. FXR1 significantly alters Cx43 and ZO-1 protein expression. Upregulation of FXR1 in the heart functionally promotes redistribution of gap junctions, contributing to an induced ventricular tachycardia in mice. Thus, we report FXR1-dependent mechanisms by which gap junctions are remodeled in DCM.
Cx43 is the major component of ventricular gap junctions, and alterations in Cx43 expression are a consistent feature in DCM. In response to increased levels of FXR1, we show that Cx43 protein expression and mRNA are reduced in isolated cardiomyocytes and intact hearts, and in human DCM samples. A reduction and reorganization in gap junctions was observed accompanying the reduced Cx43 expression. In addition to FXR1 contributing to Cx43 regulation in DCM, microRNAs are also critical regulators of gene expression in the heart. Cx43 mRNA has been shown to be the target of miR-1, miR-206, and miR-130a (for review 40 ). It is interesting to note that FXR1 interacts with the microRNA pathway via direct binding of Dicer and Argonaute 2. 20 Targeted deletion of Dicer in the heart leads to DCM, and an increase in Cx45, but not Cx43 protein expression. 41 It is possible that changes in FXR1 levels alter the miRNA pathway, possibly increasing expression of microRNAs such as miR-1, miR-206, and miR-130a, resulting in a decrease of Cx43 mRNA. Therefore, FXR1 directly represses Cx43 translation, but may be indirectly reducing its mRNA levels via the microRNA pathway.
ZO-1 directly interacts with Cx43, and the upregulation of ZO-1 has been reported to correlate with the downregulation of Cx43 protein and reduced gap junction plaque size. [9] [10] [11] In human DCM, ZO-1 expression appears to be variable, an observation seen in our study and others. [9] [10] [11] It is intriguing to note that a possible explanation for this reported variation is that ZO-1 expression varies depending on the levels of FXR1 expression. Specifically, in neonatal cardiomyocytes where expression levels of FXR1 can be controlled, we discovered that varying FXR1 expression affects ZO-1 expression; that is, low levels (≈5-fold over endogenous) of FXR1 enhance ZO-1 protein expression, whereas high levels (≈10-fold over endogenous) repress ZO-1 protein expression. Based on this finding, we predict that high variation between ZO-1 levels in human DCM samples that has been reported by many groups is because of the variation in FXR1 expression.
Fragile X RNA-binding protein family members are known for their ability to regulate mRNA translation. Fragile X proteins also localize target mRNAs and control mRNA stability. 23, 42 Although ZO-1 protein is increased in mouse models of DCM (eg, MLP-, LMOD2-, and cardiac-specific FXR1-KO mice) it does not appear to be translationally regulated by FXR1. It is interesting to note that, although total ZO-1 mRNA levels are unaffected by elevated FXR1, ZO-1 mRNA stability is increased in isolated cardiomyocytes with elevated levels of FXR1. This finding that FXR1 regulates ZO-1 mRNA stability is further supported in cardiac-specific FXR1-KO mice (fxr1 f/f Myh6-Cre), which have reduced ZO-1 mRNA levels suggesting that loss of FXR1 leads to a loss of ZO-1 mRNA stability. An increase in mRNA stability was also seen for Cx45. Although we show FXR1 interacts with Cx45, it does not appear to directly regulate its translation. Therefore, the increase in stability of Cx45 and ZO-1 mRNA on overexpression of FXR1 could be attributable to FXR1's role in stress granule formation. Stress granules are a type of cytoplasmic mRNA-protein aggregate complex that, under cellular stress, protects nontranslating mRNA from degradation (for review 43 ). It is possible that FXR1 protects ZO-1 mRNA by translocating its transcripts into stress granules. However, because loss of FXR1 results in increased ZO-1 protein, it suggests that other translational regulators are involved in regulating ZO-1 protein expression in DCM.
Studies have shown that upregulation of Cx45, in particular, superimposed on downregulation of Cx43, contributes to increased arrhythmias in the failing heart. 34, 44 Although no change was seen in levels of Cx45 protein (at the age studied) in the FXR1 overexpression mouse model, it could still contribute to the arrhythmogenic phenotype because we found that increased levels of FXR1 in the heart significantly reduced Cx43 protein expression. This decrease in Cx43 would be expected to alter the Cx43:Cx45 ratio in connexons and channels, potentially having substantial effects on channel properties, resulting in arrhythmias. Conversely, nonuniform Cx43 gap junction distribution leads to the development of reentrant circuits and clinically relevant arrhythmia in challenged hearts (eg, 45 ). Because of the inherent distribution of repolarization times throughout the myocardium that are often exacerbated in disease states, atypical dis-tribution of gap junctions may increase the likelihood that an isolated depolarization (often a premature ventricular contraction originating from a delay after depolarization) captures the myocardium in an uncontrollably propagating manner, as seen in programmed electric stimulation of AAV-3xMycFXR1-injected mice ( Figure 7A) .
The FXR1 overexpression mouse model demonstrated increased vulnerability to ventricular arrhythmias. Interesting, no detectable abnormalities in cardiac function (via echocardiography) or structural abnormalities (via staining for α-actinin and filamentous actin [data not shown]) were observed. Thus, our model may be useful for studying mechanisms leading to lethal arrhythmias in patients who have heart failure with elevated FXR1 levels. How FXR1 is regulated in disease is still not known. To date, there are no reports of FXR1 mutations associated with human disease (which is not surprising because FXR1 KO mice die shortly after birth). 13 Alterations in FXR1 expression have not only been associated with human DCM (this study and 39 ), but they have also been associated with facioscapulohumeral muscular dystrophy and various cancers (ie, lung, breast, ovarian, head and neck cancer). 46, 47 We previously reported that FXR1 interacts with its own transcript within the coding region, resulting in repressed FXR1 translation. 15 There are reports that miRNA pathways can regulate FXR1 protein expression. 48 Therefore, it is possible that FXR1 regulates its own translation in cardiomyopathy via direct interaction with its transcript or indirectly via the microRNA pathway. The precise mechanism by which FXR1 is regulated is the subject of ongoing investigations.
It is clear that FXR1 may be a promising target for therapeutic strategies to improve gap junction function. Directly targeting RNA-binding proteins for therapeutics for any disease is in the early stages. For example, investigators have identified several compounds to block the RNA-binding protein, Musashi-1, from interacting with RNA. 49, 50 Inhibition of Musashi-1's RNA-binding ability has shown promising outcomes in preclinical studies for treating colon cancer. Future studies are necessary to examine whether inhibiting FXR1's function, expression, or interaction with specific RNA can decrease the risk of arrhythmogenesis by preventing gap junction remodeling.
In summary, our findings on FXR1 and its novel target mRNAs provides a compelling mechanism for gap junction remodeling associated with dilated cardiomyopathy. To our knowledge, the results presented in this study are the first to show a connection between FXR1 levels, DCM, arrhythmogenesis, and regulation of expression of major gap junction proteins Cx43, Cx45, and ZO-1. Taken together, FXR1 is a multifunctional protein involved not only in cardiac development, but also in cardiac disease.
